QUESTIONS
Questions the literature can and cannot answer
Twelve common questions about epitalon and MOTS-c, answered from the cited record — including the ones whose honest answer is that nobody has measured it.
What does the MOTS-c peptide do?
In the body, MOTS-c is a signalling peptide encoded inside the mitochondrial genome. Its best-characterised action is to inhibit the folate cycle and de novo purine synthesis, which raises AICAR and activates AMPK — improving glucose handling and insulin sensitivity, chiefly in skeletal muscle. Under metabolic stress it also moves into the nucleus and regulates antioxidant and metabolic gene programmes in an AMPK-dependent way [5], and a 2024 study identified casein kinase 2 as a direct binding target, modulated in opposite directions in muscle and fat [1]. In mice, administration improved treadmill capacity, grip strength and gait, including in animals aged 22 to 23.5 months [4]. What it does in humans when administered has not been tested.
What are the negative side effects of MOTS-c?
There is no documented adverse-effect profile for MOTS-c, and that is a statement about the evidence rather than about safety. No human interventional trial has been conducted, so no adverse events have been systematically collected, and the corpus behind this desk carries no curated community reports for it either. Absence of reported harm under those conditions is not evidence of its absence. The documented concerns are structural: no validated human pharmacokinetics exist, material sold for research is unregulated for purity, identity and sterility, and responses appear to vary with genotype and ancestry rather than being uniform across people.
Is MOTS-c legal to buy?
MOTS-c is not approved by the FDA for any use. It is sold as a research chemical for laboratory use only, with no approved indication, formulation or dosing, and it is not for human consumption. Anti-doping authorities additionally treat it as a prohibited peptide in elite sport under hormone-and-metabolic-modulator categories, and athletes face sanctions for use. Legality of purchase and possession varies by jurisdiction and is not something this desk advises on; the regulatory fact that matters editorially is that no approved human product exists.
How often do you inject MOTS-c?
No human schedule exists, and none is published here. There is no measured human half-life, bioavailability or dose-response for MOTS-c, which means there is no pharmacological basis on which any human frequency could be derived — the animal work used rodent dosing regimens that have no established human equivalent and cannot be extrapolated into one. Schedules circulating in online communities are convention rather than evidence, and this site does not reproduce them.
What is epitalon?
Epitalon is a synthetic tetrapeptide, H-Ala-Glu-Asp-Gly-OH, also written as epithalon, epithalone or the AEDG peptide. It was derived from the amino-acid composition of epithalamin, a polypeptide extract of the bovine pineal gland, and is studied as a geroprotector — a compound investigated for effects on the biology of ageing. It has no FDA, EMA or MHRA approval and no registered indication, and is classified as a research chemical in the US, EU and UK. A 2025 review characterises it as a bioactive pineal tetrapeptide with antioxidant, neuroprotective and antimutagenic properties, while noting that its physico-chemical and structural characterisation remains limited [6].
What are the benefits of epitalon according to research?
The published findings, stated as what was measured rather than as benefits: telomerase activation and telomere elongation in cultured human cells, including telomerase-negative fetal fibroblasts [9] and, at 0.1 to 1 microgram per millilitre, normal human cell lines in 2025 [7]; stimulation of the melatonin-synthesis enzyme AANAT and the transcription factor pCREB in rat pinealocytes, with raised melatonin in the medium [8]; protection of mouse oocytes against post-ovulatory ageing through lower reactive oxygen species and modulated mitochondrial activity [12]; and, in female SHR mice, a 12.3% increase in maximum lifespan with mean lifespan unchanged, a 17.1% reduction in bone-marrow chromosome aberrations and a 6.0-fold inhibition of leukaemia with total tumour incidence unchanged [11]. The most-cited human result is observational: lower mortality over six to eight years in a cohort of 266 elderly people given the parent pineal extract, without randomisation or placebo control [10]. None of these establishes a benefit in humans taking synthetic epitalon.
What is the recommended dosage of epitalon in research protocols?
This desk publishes no dosage and makes no recommendation. What can be stated is what the cited experiments used, in their own species and settings: the mouse lifespan study administered 1.0 microgram per mouse subcutaneously on five days a month from three months of age [11]; the 2025 cell-line work used 0.1 to 1 microgram per millilitre in culture [7]; the oocyte study used 0.1 mM in vitro [12]. Those are experimental conditions, not protocols, and none of them converts into a human quantity. No published human pharmacokinetic study of epitalon exists, so no human-equivalent figure can be derived from them.
How often should epitalon be cycled, once or twice a year?
The cycling convention comes from community practice, not from the literature, and it is anecdotal, not clinical evidence. No human study has compared schedules, or tested any schedule at all. The nearest thing to a tested regimen is the SHR-mouse experiment, which dosed on five consecutive days per month from three months of age for the animals' lifetimes [11], and the human observational cohort, in which the parent pineal extract was given annually over six years in the combination arm [10]. Neither was designed to establish an interval, and neither transfers to people.
Does epitalon actually lengthen telomeres?
In cultured cells, yes, and that qualifier carries the whole answer. Epitalon induced telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts [9], and a 2025 study reproduced dose-dependent lengthening in normal human cell lines through hTERT upregulation [7]. No study on this desk measured telomere length in a living person. The 2025 work also found that in breast-cancer cell lines the lengthening ran largely through Alternative Lengthening of Telomeres, a route significant in cancer lines and only minor in normal ones [7]. Since telomerase reactivation is a hallmark of most cancers, that finding is why telomere lengthening cannot be read as unambiguously good news.
Is MOTS-c the same thing as an exercise mimetic?
It is a hypothesis with a specific origin. The 2021 study showed both that exercise induces endogenous MOTS-c in skeletal muscle and circulation, and that administered MOTS-c enhanced physical performance in mice at 2, 12 and 22 months — treadmill running capacity in the aged group improving with a reported P value of 0.000002 [4]. Those two observations together are what produced the exercise-mimetic framing. They do not demonstrate that the peptide substitutes for exercise, in mice or in people, and no human study has tested the substitution.
What is the difference between epitalon and epithalamin?
Epithalamin is a polypeptide extract of the bovine pineal gland — a mixture. Epitalon is a single synthetic tetrapeptide designed around that extract's amino-acid composition. They are chemically and legally distinct, and conflating their evidence is one of the most common errors in material written about the compound: the longest human dataset, the six-to-eight-year cohort of 266 elderly subjects, used the extract [10], while the telomerase and telomere results used the synthetic peptide [9][7]. Epithalamin has had limited clinical use in Russia for specific indications; synthetic epitalon has no regulatory approval in major Western markets.
Has either peptide been shown to extend human lifespan?
No. There is no randomised, placebo-controlled human trial of either compound, and no human study of either measuring a healthspan endpoint such as years lived without disability or time to functional decline. The strongest lifespan-adjacent human datum is observational, non-randomised, and used epithalamin rather than synthetic epitalon [10]; the strongest lifespan datum of any kind is a mouse experiment in which maximum lifespan rose 12.3% while mean lifespan did not move [11]. For MOTS-c there is no survival result at all, in any species. Anything stated more confidently than that is running ahead of the record.